Welcome to the monthly update from the Life Sciences team at S&B containing news about recent and topical developments.
Life Sciences Update - September 2018
- Technical Notices for IP in a no-deal Brexit
- Landmark NHS Legal Battle: High Court supports off-label use of Avastin
- UK Data Protection Act 2018: special category data and health provisions
- Combination products: SPC for Gilead's Truvada invalid
- The MAC report on immigration - what employers need to know
- Patent licensing - a recent High Court case highlights the limits of the exclusive jurisdiction and law clause
- Parliamentary inquiry on the impact of a no deal Brexit on health and social care
On 24 September 2018 the UK Government published four brief technical notices setting out the implications of a no-deal Brexit for intellectual property rights (IP) in the UK and the Government’s response. ‘No deal’ means that the UK would... Read more
On 21 September 2018, the NHS won a landmark case against Bayer and Novartis, who were seeking to prevent the off-label use of Avastin to treat wet age-related macular degeneration (“wet AMD”), a leading cause of sight loss in the elderly. This... Read more
UK Data Protection Act 2018: special category data and health provisions
Beverley Flynn provides her expertise on the newly passed UK Data Protection Act in relation to GDPR, and their combined implications to the life sciences sector in this article in the IBA's September Healthcare and Life Sciences Law Committee update. Read more (PDF)
Their full update is available to IBA members here.
Following a recent decision from the Court of Justice on the circumstances in which a supplementary protection certificate may be granted for a combination product, the English High Court has held that Gilead’s SPC for Truvada is invalid. In July 2018... Read more
The Migration Advisory Committee (MAC) has finally published its long awaited report on the impact on the UK labour market of the UK’s exit from the European Union. The MAC was commissioned by the Government to assess the impact of EEA migration... Read more
Where a patent licence covers more than one country the royalty clause may provide for royalties to be paid for each country according to whether the licensed product would infringe the licensed patent(s) in that country. This reflects the fact that patents... Read more
Parliamentary inquiry on the impact of a no deal Brexit on health and social care
In our August Update we wrote about guidance and technical notices which had been issued by the government addressing how the life sciences sector should prepare for Brexit. That piece can be found here.
Since the government guidance was issued, the Parliamentary Health and Social Care Committee has announced an inquiry on the impact of a no deal Brexit on health and social care and will be holding an evidence session in October. In advance of that, written submissions are currently sought from all interested parties on questions such as risks to patients, the effectiveness of the government’s and stakeholder action and what further planning is required. The Committee has expressed a particular interest in responses from patient representative groups.
The deadline for written submissions is Monday 15 October 2018 and further information, the full terms of reference and a link to the submissions page can be found here.